Cacti Asset Management LLC acquired a new position in shares of Organon & Co. (NYSE:OGN - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the company's stock, valued at approximately $246,000.
Other large investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Organon & Co. by 870.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company's stock worth $15,051,000 after purchasing an additional 906,675 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Organon & Co. by 8.3% in the first quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after acquiring an additional 820,378 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Organon & Co. by 126.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock valued at $21,370,000 after acquiring an additional 801,307 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Organon & Co. in the fourth quarter valued at $11,892,000. Finally, Siemens Fonds Invest GmbH acquired a new stake in Organon & Co. in the fourth quarter valued at $8,998,000. Institutional investors own 77.43% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, BNP Paribas upgraded shares of Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $17.33.
Check Out Our Latest Stock Analysis on Organon & Co.
Organon & Co. Stock Performance
NYSE:OGN traded up $0.33 during mid-day trading on Thursday, reaching $10.78. 1,580,784 shares of the company's stock were exchanged, compared to its average volume of 4,396,744. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. Organon & Co. has a one year low of $8.01 and a one year high of $20.48. The firm has a market capitalization of $2.80 billion, a PE ratio of 4.02, a price-to-earnings-growth ratio of 0.94 and a beta of 0.60. The business's fifty day simple moving average is $9.67 and its two-hundred day simple moving average is $10.78.
Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating the consensus estimate of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. During the same period last year, the firm earned $1.12 EPS. The business's quarterly revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. Analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.
Organon & Co. Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were issued a dividend of $0.02 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 annualized dividend and a dividend yield of 0.7%. Organon & Co.'s payout ratio is 2.97%.
About Organon & Co.
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Featured Stories
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
